TY  - JOUR
AU  - Hörsch, Dieter
AU  - Anthony, Lowell
AU  - Gross, David J
AU  - Valle, Juan W
AU  - Welin, Staffan
AU  - Benavent, Marta
AU  - Caplin, Martyn
AU  - Pavel, Marianne
AU  - Bergsland, Emily
AU  - Öberg, Kjell
AU  - Kassler-Taub, Kenneth B
AU  - Binder, Polina
AU  - Banks, Phillip
AU  - Lapuerta, Pablo
AU  - Kulke, Matthew H
PY  - 2021
DO  - 10.1159/000516958
UR  - https://hdl.handle.net/10668/27804
T2  - Neuroendocrinology
AB  - Telotristat ethyl is indicated for use in combination with somatostatin analogs (SSAs) to treat carcinoid syndrome (CS) diarrhea uncontrolled by SSAs alone in adults, but long-term safety and efficacy data beyond 48 weeks are needed. The aims of the...
LA  - en
KW  - Carcinoid syndrome
KW  - Diarrhea
KW  - Quality of life
KW  - Safety and tolerability
KW  - Telotristat ethyl
KW  - Adult
KW  - Humans
KW  - Malignant Carcinoid Syndrome
KW  - Phenylalanine
KW  - Pyrimidines
KW  - Quality of Life
KW  - Treatment Outcome
TI  - Long-Term Treatment with Telotristat Ethyl in Patients with Carcinoid Syndrome Symptoms: Results from the TELEPATH Study.
TY  - research article
VL  - 112
ER  -